A treatment planning platform for interstitial microwave hyperthermia was developed for practical, free-hand clinical implants. Such implants, consisting of non-parallel, moderately curved antennas with varying insertion depths, are used in HDR brachytherapy for treating locally advanced cancer.
Numerical models for commercially available MA251 antennas (915 MHz, BSD Medical) were developed in COMSOL Multiphysics, a finite element analysis software package. To expedite treatment planning, electric fields, power deposition and temperature rises were computed for a single straight antenna in 2D axisymmetric geometry. A precomputed library of electric field and temperature solutions was created for a range of insertion depths (5-12 cm) and blood perfusion rates (0.5-5 kg/m3/s). 3D models of multiple antennas and benchtop phantoms experiments using temperature-sensitive liquid crystal paper to monitor heating by curved antennas were performed for comparative evaluation of the treatment planning platform.
A patient-customizable hyperthermia treatment planning software package was developed in MATLAB with capabilities to interface with a commercial radiation therapy planning platform (Oncentra, Nucleotron), import patient and multicatheter implant geometries, calculate insertion depths, and perform hyperthermia planning with antennas operating in asynchronous or synchronous mode. During asynchronous operation, the net power deposition and temperature rises were approximated as a superposition sum of the respective quantities for one single antenna. During synchronous excitation, a superposition of complex electrical fields was performed with appropriate phasing to compute power deposition. Electric fields and temperatures from the pre-computed single-antenna library were utilized following appropriate non-rigid coordinate transformations. Comparison to 3D models indicated that superposition of electric fields around parallel antennas is valid when they are at least 15 mm apart. Phantom experiments with curved antennas produced temperature profiles quite similar to those created using the planning system.
The hyperthermia planning software allowed users to select power and phasing, assess the corresponding 3D contours of energy and temperature, and optimize treatment parameters through gradient search techniques. The system produces fairly accurate temperature distributions in cases when the antennas are at least 15 mm apart.
An ultrasound applicator for endoluminal thermal therapy of pancreatic tumors has been introduced and evaluated through acoustic/biothermal simulations and ex vivo experimental investigations. Endoluminal therapeutic ultrasound constitutes a minimally invasive conformal therapy and is compatible with ultrasound or MR-based image guidance. The applicator would be placed in the stomach or duodenal lumen, and sonication would be performed through the luminal wall into the tumor, with concurrent water cooling of the wall tissue to prevent its thermal injury. A finite-element (FEM) 3D acoustic and biothermal model was implemented for theoretical analysis of the approach. Parametric studies over transducer geometries and frequencies revealed that operating frequencies within 1-3 MHz maximize penetration depth and lesion volume while sparing damage to the luminal wall. Patient-specific FEM models of pancreatic head tumors were generated and used to assess the feasibility of performing endoluminal ultrasound thermal ablation and hyperthermia of pancreatic tumors. Results indicated over 80% of the volume of small tumors (~2 cm diameter) within 35 mm of the duodenum could be safely ablated in under 30 minutes or elevated to hyperthermic temperatures at steady-state. Approximately 60% of a large tumor (~5 cm diameter) model could be safely ablated by considering multiple positions of the applicator along the length of the duodenum to increase coverage. Prototype applicators containing two 3.2 MHz planar transducers were fabricated and evaluated in ex vivo porcine carcass heating experiments under MR temperature imaging (MRTI) guidance. The applicator was positioned in the stomach adjacent to the pancreas, and sonications were performed for 10 min at 5 W/cm2 applied intensity. MRTI indicated over 400C temperature rise in pancreatic tissue with heating penetration extending 3 cm from the luminal wall.
Image-guided thermal interventions have been proposed for potential palliative and curative treatments of pancreatic
tumors. Catheter-based ultrasound devices offer the potential for temporal and 3D spatial control of the energy
deposition profile. The objective of this study was to apply theoretical and experimental techniques to investigate the
feasibility of endogastric, intraluminal and transgastric catheter-based ultrasound for MR guided thermal therapy of
pancreatic tumors. The transgastric approach involves insertion of a catheter-based ultrasound applicator (array of 1.5
mm OD x 10 mm transducers, 360° or sectored 180°, ~7 MHz frequency, 13-14G cooling catheter) directly into the
pancreas, either endoscopically or via image-guided percutaneous placement. An intraluminal applicator, of a more
flexible but similar construct, was considered for endoscopic insertion directly into the pancreatic or biliary duct. An
endoluminal approach was devised based on an ultrasound transducer assembly (tubular, planar, curvilinear) enclosed in
a cooling balloon which is endoscopically positioned within the stomach or duodenum, adjacent to pancreatic targets
from within the GI tract. A 3D acoustic bio-thermal model was implemented to calculate acoustic energy distributions
and used a FEM solver to determine the transient temperature and thermal dose profiles in tissue during heating. These
models were used to determine transducer parameters and delivery strategies and to study the feasibility of ablating 1-3
cm diameter tumors located 2-10 mm deep in the pancreas, while thermally sparing the stomach wall. Heterogeneous
acoustic and thermal properties were incorporated, including approximations for tumor desmoplasia and dynamic
changes during heating. A series of anatomic models based on imaging scans of representative patients were used to
investigate the three approaches. Proof of concept (POC) endogastric and transgastric applicators were fabricated and
experimentally evaluated in tissue mimicking phantoms, ex vivo tissue and in vivo canine model under multi-slice MR thermometry. RF micro-coils were evaluated to enable active catheter-tracking and prescription of thermometry slice
positions. Interstitial and intraluminal ultrasound applicators could be used to ablate (t43>240min) tumors measuring 2.3-3.4 cm in diameter when powered with 20-30 W/cm2 at 7 MHz for 5-10 min. Endoluminal applicators with planar and
curvilinear transducers operating at 3-4 MHz could be used to treat tumors up to 20-25 mm deep from the stomach wall
within 5 min. POC devices were fabricated and successfully integrated into the MRI environment with catheter tracking,
real-time thermometry and closed-loop feedback control.
Preferential heating of bone due to high ultrasound attenuation may enhance thermal ablation performed with cathetercooled
interstitial ultrasound applicators in or near bone. At the same time, thermally and acoustically insulating cortical
bone may protect sensitive structures nearby. 3D acoustic and biothermal transient finite element models were
developed to simulate temperature and thermal dose distributions during catheter-cooled interstitial ultrasound ablation
near bone. Experiments in ex vivo tissues and tissue-mimicking phantoms were performed to validate the models and to
quantify the temperature profiles and ablated volumes for various distances between the interstitial applicator and the
bone surface. 3D patient-specific models selected to bracket the range of clinical usage were developed to investigate
what types of tumors could be treated, applicator configurations, insertion paths, safety margins, and other parameters.
Experiments show that preferential heating at the bone surface decreases treatment times compared to when bone is
absent and that all tissue between an applicator and bone can be ablated when they are up to 2 cm apart. Simulations
indicate that a 5-7 mm safety margin of normal bone is needed to protect (thermal dose < 6 CEM43°C and T < 45°C) sensitive structures behind ablated bone. In 3D patient-specific simulations, tumors 1.0-3.8 cm (L) and 1.3-3.0 cm (D) near or within bone were ablated (thermal dose > 240 CEM43°C) within 10 min without damaging the nearby spinal cord, lungs, esophagus, trachea, or major vasculature. Preferential absorption of ultrasound by bone may provide
improved localization, faster treatment times, and larger treatment zones in tumors in and near bone compared to other
heating modalities.
A clinical treatment delivery platform has been developed and is being evaluated in a clinical pilot study for providing
3D controlled hyperthermia with catheter-based ultrasound applicators in conjunction with high dose rate (HDR)
brachytherapy. Catheter-based ultrasound applicators are capable of 3D spatial control of heating in both angle and
length of the devices, with enhanced radial penetration of heating compared to other hyperthermia technologies.
Interstitial and endocavity ultrasound devices have been developed specifically for applying hyperthermia within HDR
brachytherapy implants during radiation therapy in the treatment of cervix and prostate. A pilot study of the
combination of catheter based ultrasound with HDR brachytherapy for locally advanced prostate and cervical cancer has
been initiated, and preliminary results of the performance and heating distributions are reported herein. The treatment
delivery platform consists of a 32 channel RF amplifier and a 48 channel thermocouple monitoring system. Controlling
software can monitor and regulate frequency and power to each transducer section as required during the procedure.
Interstitial applicators consist of multiple transducer sections of 2-4 cm length × 180 deg and 3-4 cm × 360 deg. heating
patterns to be inserted in specific placed 13g implant catheters. The endocavity device, designed to be inserted within a
6 mm OD plastic tandem catheter within the cervix, consists of 2-3 transducers × dual 180 or 360 deg sectors. 3D
temperature based treatment planning and optimization is dovetailed to the HDR optimization based planning to best
configure and position the applicators within the catheters, and to determine optimal base power levels to each
transducer section. To date we have treated eight cervix implants and six prostate implants. 100 % of treatments
achieved a goal of >60 min duration, with therapeutic temperatures achieved in all cases. Thermal dosimetry within the
hyperthermia target volume (HTV) and clinical target volume (CTV) are reported. Catheter-based ultrasound
hyperthermia with HDR appears feasible with therapeutic temperature coverage of the target volume within the prostate
or cervix while sparing surrounding more sensitive regions.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.